E2F7 and lung cancer: Liu et al. (2018) have revealed that E2F7 was reported significantly overexpressed in ER-positive breast cancer than healthy breast tissues and then led to tamoxifen resistance in breast cancer cells. Additionally, overexpressed E2F7 could be suggested as a significant biomarker to identify the high-risk and low-risk groups of patients with lung cancer, which is also in consistence with our report (Sun et al., 2018).